A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

NCT07399444 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)

Interventions

BIOLOGICAL: LVIVO-TaVec400 product

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

Nanjing Legend Biotech Co.